Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial Testing Durvalumab Combined With Endocrine Therapy in Patients With ER+/Her2- Breast Cancer Eligible for Neoadjuvant Endocrine Therapy And Who Present CD8+ T Cell Infiltration After 4-6 Weeks Exposure to Immune-Attractant

NCT02997995 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT02997995
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02997995 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial Testing Durvalumab Combined With Endocrine Therapy in Patients With ER+/Her2- Breast Cancer Eligible for Neoadjuvant Endocrine Therapy And Who Present CD8+ T Cell Infiltration After 4-6 Weeks Exposure to Immune-Attractant
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Completed
Start date
February 15, 2017
Completion date
August 28, 2020
Enrollment
61 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, estrogen receptor positive tumor, hormone antagonist, menopause